KDM1A and nonpapillary renal cell carcinoma: As the anticancer effect of Arborinine and its potential target Lysine Demethylase 1A (KDM1A or LSD1) have been reported in multiple types of cancer (12, 13), simply validating such effect and signaling in ccRCC are predictable.